USPTO reissues Xenogen patent for in vivo imaging
Xenogen Corp. announced this week that the U.S. Patent and Trademark Office (USPTO) has reissued a patent on its proprietary biophotonic imaging technology, exclusively licensed to the company.
The patent, U.S. Patent No. 5,650,135, was issued for Xenogen's unique methods of real time, non-invasive in vivo optical imaging of whole animals, or biophotonic imaging, and will remain in force until 2017.
Biophotonic imaging substantially improves the timeliness and quality of data generated in pre-clinical drug development and requires the use of up to 60 percent fewer animals in the research process than traditional methods, said Xenogen. Pharmaceutical and biotechnology companies such as Merck & Company Inc., Pfizer Inc., Novartis AG and Chiron Corp., and academic or research institutions such as the University of Texas, M.D. Anderson Cancer Center, The National Institutes of Health and Yale University are currently using Xenogen's technology.
The patent, U.S. Patent No. 5,650,135, was issued for Xenogen's unique methods of real time, non-invasive in vivo optical imaging of whole animals, or biophotonic imaging, and will remain in force until 2017.
Biophotonic imaging substantially improves the timeliness and quality of data generated in pre-clinical drug development and requires the use of up to 60 percent fewer animals in the research process than traditional methods, said Xenogen. Pharmaceutical and biotechnology companies such as Merck & Company Inc., Pfizer Inc., Novartis AG and Chiron Corp., and academic or research institutions such as the University of Texas, M.D. Anderson Cancer Center, The National Institutes of Health and Yale University are currently using Xenogen's technology.